2017
DOI: 10.1016/j.ejphar.2017.06.029
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease, European Journal of Pharmacology, http://dx.doi.org/10.1016Pharmacology, http://dx.doi.org/10. /j.ejphar.2017 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
43
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
9

Relationship

4
5

Authors

Journals

citations
Cited by 77 publications
(45 citation statements)
references
References 63 publications
1
43
1
Order By: Relevance
“…APP/PS1 mice show insulin desensitization that can be reversed by GLP-1 analogues (Long-Smith et al, 2013), and the normalization of insulin signaling could be the reason for the normalization of PI3K/AKT signaling. Previously, we have shown the such dual agonists have protective effects in animal models of Parkinson (Cao et al, 2016a;Hölscher, 2016;Jalewa et al, 2017;Ji et al, 2016;Yuan et al, 2017), and stroke (Han et al, 2016), demonstrating the great potential that such dual receptor agonists show. It is interesting that the neuroprotection of DA5-CH treatment achieves almost-complete reverse effect on the behaviors or the pathologies, while it can only partially ameliorate the PI3K/AKT/GSK3β signaling pathway.…”
Section: Discussionmentioning
confidence: 92%
“…APP/PS1 mice show insulin desensitization that can be reversed by GLP-1 analogues (Long-Smith et al, 2013), and the normalization of insulin signaling could be the reason for the normalization of PI3K/AKT signaling. Previously, we have shown the such dual agonists have protective effects in animal models of Parkinson (Cao et al, 2016a;Hölscher, 2016;Jalewa et al, 2017;Ji et al, 2016;Yuan et al, 2017), and stroke (Han et al, 2016), demonstrating the great potential that such dual receptor agonists show. It is interesting that the neuroprotection of DA5-CH treatment achieves almost-complete reverse effect on the behaviors or the pathologies, while it can only partially ameliorate the PI3K/AKT/GSK3β signaling pathway.…”
Section: Discussionmentioning
confidence: 92%
“…Recently, multiple receptor agonists have been developed to treat type II diabetes (Finan et al, 2013;Finan et al, 2015). We have tested novel dual GLP-1/GIP receptor agonists that showed good neuroprotective effects that are superior to single GLP-1 analogues (Cao et al, 2016;Jalewa et al, 2017;Ji et al, 2016b;Yuan et al, 2017). The novel dual agonist DA3-CH was found to be superior to liraglutide in a mouse model of Parkinson's disease (Yuan et al, 2017), demonstrating that the strategy of activating more than one incretin receptor type offers an advantage over single receptor agonists.…”
Section: Discussionmentioning
confidence: 99%
“…Lixisenatide (an incretin mimetic like exenatide, based on the structure of exendin-4) and liraglutide, dulaglutide and albiglutide (based on the structure of human GLP-1 and termed GLP-1 analogues). In PD models, data exists for liraglutide and lixisenatide which have similarly demonstrated neuroprotective effects in animal-toxin models of PD, preventing MPTP-, 6-OHDA-and rotenone-induced dopaminergic cell loss and motor impairments which were associated with reduction in pro-apoptotic signalling,pro-inflammatory cytokine production and promotion of neurotophic factors such as GDNF[129][130][131][132].…”
mentioning
confidence: 99%